KP-10614
KP-10614 is a potent, orally active platelet aggregation inhibitor. KP-10614 inhibits platelet aggregation induced by ADP with IC50 of 1 nM. KP-10614 causes dose-dependent inhibition of ex vivo platelet aggregation in rats. KP-10614 shows antithrombotic effects in various thrombosis models. KP-10614 can be used for thrombotic diseases research[1].
Product Specifications
CAS Number
[130273-99-3]
UNSPSC
12352211
Target
Others
Related Pathways
Others
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Smiles
CCC#CC[C@H](C)[C@H](O)/C=C/[C@@H]1[C@]2([H])[C@@](C[C@H]1O)([H])C=C(C2)/C=C\CCC(O)=O
Molecular Formula
C23H32O4
Molecular Weight
372.50
References & Citations
[1]Kanayama T, et al. Antithrombotic effects of KP-10614, a novel and stable prostacyclin (PGI2) analog. J Pharmacol Exp Ther. 1990 Dec;255 (3) :1210-7.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6230612-01 0.1 mL
ULK2 (unc-51-like Kinase 2 (C. elegans), KIAA0623, Unc51.2) (MaxLight 650)
Ask
View Details 
MBS6230612-02 5x 0.1 mL
ULK2 (unc-51-like Kinase 2 (C. elegans), KIAA0623, Unc51.2) (MaxLight 650)
Ask
View Details